The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CEACAM6 as a candidate biomarker for pelareorep sensitivity in pancreatic adenocarcinoma (PDAC).
 
Anne M. Noonan
Consulting or Advisory Role - Exelixis; Exelixis; Exelixis; Exelixis; Helsinn Healthcare; Helsinn Healthcare; Helsinn Healthcare; Helsinn Healthcare; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics
 
Jacob Yount
No Relationships to Disclose
 
Jason David
No Relationships to Disclose
 
Mindy Hoang
No Relationships to Disclose
 
Colin W. Stets
No Relationships to Disclose
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Amgen; Amgen; Amgen; Amgen; Amgen (Inst); Amgen (Inst); AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Immuneering; Immuneering; Immuneering; Immuneering; Imugene; Imugene; Imugene; Imugene; Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly; Lilly; Lilly; Lilly; Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); NCCN; NCCN; NCCN; NCCN; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Regeneron; Regeneron; Regeneron; Regeneron; Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - NCCN; NCCN; NCCN; NCCN; NCI; NCI; NCI; NCI; Oncolytics; Oncolytics; Oncolytics; Oncolytics
Other Relationship - ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Exelixis; Exelixis; Exelixis; Exelixis; Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Polaris; Polaris; Polaris; Polaris; Sillajen; Sillajen; Sillajen; Sillajen
 
Ying Huang
No Relationships to Disclose
 
Wendy L. Frankel
No Relationships to Disclose
 
Cynthia Dawn Timmers
Stock and Other Ownership Interests - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Seagen; Seagen; Seagen; Seagen
 
John L. Hays
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Eisai; Eisai; Eisai; Eisai; Merck; Merck; Merck; Merck; Tesaro; Tesaro; Tesaro; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Merck; Merck; Merck; Merck; Tesaro; Tesaro; Tesaro; Tesaro
 
James Lin Chen
Consulting or Advisory Role - Immune Design; Immune Design; Immune Design; Immune Design; Novartis; Novartis; Novartis; Novartis; Syapse; Syapse; Syapse; Syapse
Speakers' Bureau - Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Novartis; Novartis; Novartis; Novartis
Research Funding - Eisai; Eisai; Eisai; Eisai
Patents, Royalties, Other Intellectual Property - MatchTX; MatchTX; MatchTX; MatchTX